Colon cancer survivors who are moderately or severely obese face tougher survival odds following treatment compared with their normal-weight peers, a new study reveals.
189347 items (189347 unread) in 47 feeds
World Health Organization
(226 unread)
Media
(146550 unread)
Bird Flu
(3059 unread)
Diabetes
(8426 unread)
Cholesterol
(3564 unread)
Cancer
(15116 unread)
HIV
(7259 unread)
Women
(3814 unread)
Men
(1333 unread)
Colon cancer survivors who are moderately or severely obese face tougher survival odds following treatment compared with their normal-weight peers, a new study reveals.
Dendreon Corporation today announced updated results from its pivotal Phase 3 IMPACT study demonstrating that PROVENGE extends overall survival in men with metastatic, castrate-resistant prostate cancer .
At left, Stephen Duckett, president and CEO of Alberta Health Services. At right, Alberta Premier Ed Stelmach.
New breakthrough treatments for the most common cancers could soon come from cutting-edge research into some of the world's rarest tumors.
TWO patients had a delayed cancer diagnosis when almost 58,000 X-rays taken at Tallaght Hospital in Dublin were not reviewed by a consultant radiologist.